Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thermo Fisher Scientific Reports First Quarter 2013 Results

Published: Thursday, April 25, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
Adjusted earnings per share grew 17% to a record $1.37 with revenue increased 4% to a first quarter record of $3.19 billion.

First Quarter 2013 Highlights:

• Adjusted operating margin expanded 40 basis points to 19.3%

• Launched innovative new products at Pittcon that strengthened analytical technologies offering, including major upgrade of gold-standard Chromeleon chromatography data system

• Deployed $90 million in the quarter to repurchase 1.3 million shares

• After quarter-end, announced agreement to acquire Life Technologies, creating an unrivaled industry leader serving research, specialty diagnostics and applied markets

Adjusted EPS, adjusted operating income, adjusted operating margin and free cash flow are non-GAAP measures that exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Financial Measures.”

“We’re pleased with our solid first quarter results, with good performance on the top line,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “We also extended our track record of strong adjusted EPS growth, delivering a 17% increase year over year. Although the macro environment played out at the lower end of our expectations, our teams executed well to continue our growth momentum into 2013.

“It was a great quarter for product innovation, with a strong showing at Pittcon that reinforced our leadership in analytical technologies. Among the highlights, we introduced the next generation of our premier chromatography software, Chromeleon 7.2. This upgrade allows mass spectrometry and chromatography systems to be controlled on one data platform for the first time and facilitates the flow of information, for example, between research labs. For applied markets, we launched the iCAP 7000 elemental analyzer and the picoSpin 45 miniature NMR spectrometer, both of which extend the use of research-grade technologies to a broader customer base.

“From a geographic perspective, our industry-leading scale in Asia-Pacific continues to drive growth. This is particularly evident in China, where our depth of capabilities is helping our customers there improve healthcare, the environment and food safety.

“Finally, the recent announcement of our agreement to acquire Life Technologies will take our leadership position to a new level, creating an unrivaled leader in our industry. We look forward to closing the transaction and executing a successful integration to create significant value for our customers and shareholders alike.”

First Quarter 2013

For the first quarter of 2013, adjusted EPS grew 17% to a record $1.37, versus $1.17 in the first quarter of 2012. Revenue for the quarter grew 4% to $3.19 billion in 2013, versus $3.06 billion in 2012. Organic revenue grew 3%, with currency translation lowering revenue by 1% and acquisitions increasing revenue by 3%. Adjusted operating income for the first quarter of 2013 increased 7% compared with the year-ago period, and adjusted operating margin expanded to 19.3%, compared with 18.9% in the first quarter of 2012.

GAAP diluted EPS for the first quarter of 2013 was $0.93, versus $0.75 in the same quarter last year. GAAP operating income for the first quarter of 2013 increased 7% to $387 million, compared with $362 million in 2012. GAAP operating margin increased to 12.1%, compared with 11.8% in the first quarter of 2012.

Annual Guidance for 2013

Casper added, “We’re updating our 2013 guidance based on our solid first quarter performance and our decision to suspend share buybacks in light of our pending acquisition of Life Technologies.”

The company is updating its revenue guidance range from $12.80 to $13.00 billion to a new range of $12.84 to $13.00 billion, resulting in 3% to 4% growth year over year. It is also updating full year 2013 adjusted EPS guidance from $5.32 to $5.46 to a new range of $5.27 to $5.39, reflecting the suspension of share buybacks and tightening of its revenue range. This would lead to 7% to 9% growth over 2012.

The 2013 guidance does not include the acquisition of Life Technologies or the impact of related financing activities. As previously stated, the guidance does not include any other future acquisitions or divestitures, and is based on current foreign exchange rates. In addition, the adjusted EPS estimate excludes amortization expense for acquisition-related intangible assets and certain other items detailed later in this press release under the heading “Use of Non-GAAP Financial Measures.”

Segment Results

Management uses adjusted operating results to monitor and evaluate performance of the company’s three business segments, as highlighted below.

Analytical Technologies Segment

In the first quarter of 2013, Analytical Technologies Segment revenue was $978 million, compared with revenue of $980 million in the first quarter of 2012. Segment adjusted operating income decreased 2% in the first quarter of 2013, and adjusted operating margin was 18.0%, versus 18.2% in the 2012 quarter.

Specialty Diagnostics Segment

Specialty Diagnostics Segment revenue in the first quarter increased 10% to $806 million in 2013, compared with revenue of $732 million in the first quarter of 2012. Segment adjusted operating income increased 19% in the first quarter of 2013, and adjusted operating margin increased to 27.5%, versus 25.5% in the 2012 quarter.

Laboratory Products and Services Segment

In the first quarter of 2013, Laboratory Products and Services Segment revenue increased 5% to $1.54 billion, compared with revenue of $1.48 billion in the first quarter of 2012. Segment adjusted operating income increased 3% in the first quarter of 2013, and adjusted operating margin was 14.1%, versus 14.3% in the 2012 quarter.

Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted EPS, adjusted operating income and adjusted operating margin, which exclude restructuring and other costs/income and amortization of acquisition-related intangible assets. Adjusted EPS also excludes certain other gains and losses, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events and discontinued operations. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. We also use a non-GAAP measure, free cash flow, which excludes operating cash flows from discontinued operations and deducts net capital expenditures. We believe that the use of non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s performance, especially when comparing such results to previous periods or forecasts.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Advancing Lithium-Ion Battery Research
The increasing number of components in a lithium-ion battery makes it essential to use a variety of analytical methods to attain complete characterization.
Wednesday, October 28, 2015
Automating Deep Characterization of Biotherapeutic Proteins
Thermo's new PepFinder software streamlines relative and absolute quantitation, and identification of proteins from biological samples using LC-MS.
Thursday, June 19, 2014
Thermo Scientific Chromatography Columns/Consumables Catalog Goes Mobile
2014-15 Chromatography Columns and Consumables Catalog now available in print, pdf and interactive mobile versions.
Thursday, February 27, 2014
Thermo Collaborates with Leading EU and UK Pesticide Testing Labs
The company's Pesticide Analysis Center of Excellence provides technology, consultation and support.
Tuesday, November 19, 2013
Thermo Scientific at ASMS 2013
Learn how scientists and researchers are transforming science by applying innovative solutions to a wide range of qualitative and quantitative applications.
Monday, May 13, 2013
Thermo Fisher Scientific to Acquire Life Technologies
Transaction expected to create an unrivaled leader in serving research, specialty diagnostics and applied markets.
Wednesday, April 17, 2013
Thermo Fisher Scientific to Acquire Life Technologies Corporation
The definitive agreement will see Thermo Fisher will acquire Life Technologies for $76.00 in cash per fully diluted common share or approximately $13.6 billion.
Monday, April 15, 2013
Thermo Fisher Scientific Facilities Achieve ISO 13485 Certification
The facilities in San Jose, CA and Franklin, MA have achieved the internationally recognized standard of quality management for the design and manufacture of medical devices.
Thursday, April 04, 2013
Thermo Fisher Scientific to Acquire picoSpin
Thermo Fisher Scientific Inc. has completed a purchase of picoSpin, LLC, creators of the world’s first miniature NMR spectrometer.
Friday, December 21, 2012
Hyperion Succesfully Completes Laboratory Infrastructure Project for Hellenic Petroleum
Hyperion and the Hellenic Petroleum Group have completed a major upgrade and extension project for the LIMS at three Greek petroleum refineries of the Group.
Wednesday, November 21, 2012
Thermo Fisher Scientific Reports Q3 Revenue and EPS Results
Revenue increased 5% to a record $3.09 billion for the third quarter with adjusted operating income rising 5% to $576 million.
Wednesday, October 24, 2012
Thermo Fisher Scientific and Immundiagnostik Collaborate
The collaboration aims to develop novel mass spectrometry-based assays for qualitative and quantitative analysis of proteins and peptides.
Wednesday, October 17, 2012
Thermo Fisher Scientific and bioMérieux Renew Partnership
The companies have renewed their non-exclusive, long-term, royalty-bearing agreement for Procalcitonin testing.
Wednesday, October 03, 2012
Seminars on Advanced Solutions for Nutraceutical Analysis
Seminar sessions will discuss Company’s chromatography and elemental analysis techniques to optimize nutraceutical processes.
Tuesday, September 25, 2012
Thermo Scientific Opens Molecular Biology Center of Excellence in Lithuania
New facility expands R&D and manufacturing capabilities in eastern Europe for molecular, protein and cellular biology products.
Friday, September 21, 2012
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Structure of Essential Digestive Enzyme Uncovered
Using a powerful combination of techniques from biophysics to mathematics, researchers have revealed new insights into the mechanism of a liver enzyme that is critical for human health.
Air Pollution Linked to Heart Disease
10-year project revealed air pollutants accelerate plaque build-up in arteries to the heart.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Following Tricky Triclosan
Antibacterial product flows through streams, crops.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!